Few people in the UK with early stage Alzheimer’s disease are likely to be suitable for the latest drugs that aim to halt progress of the condition, yet many are nevertheless likely to be referred for these treatments, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.